A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
Public ClinicalTrials.gov record NCT02985957. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
Study identification
- NCT ID
- NCT02985957
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 351 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Ipilimumab Biological
- Cabazitaxel Drug
- Prednisone Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 2017
- Primary completion
- Apr 4, 2022
- Completion
- Jan 6, 2025
- Last update posted
- Dec 21, 2025
2017 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0074 | Tucson | Arizona | 85711 | — |
| Local Institution - 0046 | Marietta | Georgia | 30060 | — |
| Local Institution - 0011 | Chicago | Illinois | 60637 | — |
| Local Institution - 0076 | Minneapolis | Minnesota | 55404 | — |
| Local Institution - 0008 | St Louis | Missouri | 63110 | — |
| Local Institution - 0075 | Las Vegas | Nevada | 89169 | — |
| Local Institution - 0078 | Albany | New York | 12208 | — |
| Local Institution - 0065 | Lake Success | New York | 11042 | — |
| Local Institution - 0001 | New York | New York | 10029 | — |
| Local Institution - 0077 | Tigard | Oregon | 97223 | — |
| Local Institution - 0047 | Allentown | Pennsylvania | 18105 | — |
| Local Institution - 0010 | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution - 0067 | Charleston | South Carolina | 29425 | — |
| Local Institution - 0079 | Austin | Texas | 78731 | — |
| Local Institution - 0002 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02985957, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2025 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02985957 live on ClinicalTrials.gov.